Amicus Therapeutics, Inc. (NASDAQ:FOLD) is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.22 per share.
Looking ahead, the full year loss are expected at $ 1 per share on the revenues of $ 256.88 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 250.00 million ~ $ 260.00 million
Click Here For More Historical Outlooks Of Amicus Therapeutics, Inc.
Previous Quarter Performance
Amicus Therapeutics, Inc. communicated loss for the second quarter of $ 0.20 per share, from the revenue of $ 62.35 million. Wall street analysts are predicting, FOLD to report 2Q20 loss of $ 0.26 per share from revenue of $ 62.38 million. The bottom line results beat street analysts by $ 0.06 or 23.08 percent, at the same time, top line results fell short of analysts by $ 0.03 million or 0.05 percent.
Stock Performance
Shares of Amicus Therapeutics, Inc. traded up $ 1.77 or 9.33 percent on Wednesday, reaching $ 20.74 with volume of 2.76 million shares. Amicus Therapeutics, Inc. has traded high as $ 20.93 and has cracked $ 18.93 on the downward trend
The closing price of $ 20.74, representing a 203.52 % increase from the 52 week low of $ 6.25 and a 9.36 % decrease over the 52 week high of $ 20.93.
The company has a market capital of $ 5.37 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Amicus Therapeutics, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.amicusrx.com
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
